TNON Form 4: Director receives 21,464 RSUs with split 2026 vesting

Rhea-AI Filing Summary

Tenon Medical (TNON) reported a director equity grant. On 10/13/2025, a director received 21,464 restricted stock units (RSUs) at a price of $0, as disclosed in a Form 4 filing.

Each RSU represents the right to receive one share of common stock. The vesting schedule splits evenly: 50% of the RSUs vest and convert into common stock on January 1, 2026, and the remaining 50% vest and convert on July 31, 2026. Following the grant, the reporting person held 21,464 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

HOWARD IVAN

(Last) (First) (Middle)

104 COOPER COURT

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/13/2025		A		21,464		(2)	(2)	Common Stock	21,464	$0	21,464	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

	/s/ Ivan Howard	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tenon Medical (TNON) report in this Form 4?

A director was granted 21,464 RSUs on 10/13/2025 at a price of $0.

How do the RSUs convert for the Tenon Medical (TNON) grant?

Each RSU converts into one share of common stock when vested.

What is the vesting schedule for the 21,464 RSUs at TNON?

50% vest on January 1, 2026 and 50% vest on July 31, 2026.

How many derivative securities did the reporting person hold after the transaction?

The reporting person held 21,464 derivative securities following the transaction.

What is the ownership form of the reported RSUs?

The RSUs are held directly (D) by the reporting person.

What role does the reporting person have at Tenon Medical (TNON)?

The reporting person is a Director.